source
- FDA mandates label update for all GLP-1 drugs to warn of rare eye disease riskThe FDA issued a class‑wide labeling requirement for all approved GLP‑1 receptor agonists, adding a warning about non‑arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that…
- Compass Pathways to file FDA approval for psilocybin depression therapy within weeksCompass Pathways announced it will complete its FDA filing for the psilocybin‑based depression treatment COMP360 in the next two weeks. The company expects the rolling submission to enable a drug…